Alpha Cognition Inc. (ACOG) stock
ACOGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/3066% above fair value
$8.30−0.26 (-3.04%)
Close on Nov 13, 2026Market cap $180.76MP/E –Yield –
Alpha Cognition r&d expenses
Research and development expenses are spending on new products and technology.
Alpha Cognition's R&D Expenses for the twelve months ending Sep 30, 2026 was $5.00M, up 111.7% year over year. For fiscal 2025 it was $1.87M, down 52.4% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.87M | -52.4% |
| FY2024 | Dec 31, 2024 | $3.92M | -19.7% |
| FY2023 | Dec 31, 2023 | $4.88M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.34M | +161.8% |
| Q2 FY2026 | Jun 30, 2026 | $2.01M | +394.6% |
| Q1 FY2026 | Mar 31, 2026 | $1.10M | +173.8% |
| Q4 FY2025 | Dec 31, 2025 | $547.63K | -47.4% |
| Q3 FY2025 | Sep 30, 2025 | $513.78K | -48.4% |
| Q2 FY2025 | Jun 30, 2025 | $406.14K | -58.0% |
| Q1 FY2025 | Mar 31, 2025 | $400.42K | -56.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.04M | -6.3% |
| Q3 FY2024 | Sep 30, 2024 | $996.03K | -30.3% |
| Q2 FY2024 | Jun 30, 2024 | $967.20K | -22.4% |
| Q1 FY2024 | Mar 31, 2024 | $916.72K | – |
| Q4 FY2023 | Dec 31, 2023 | $1.11M | – |
| Q3 FY2023 | Sep 30, 2023 | $1.43M | – |
| Q2 FY2023 | Jun 30, 2023 | $1.25M | – |
See a number that looks wrong?